Clinical utility of circulating tumor DNA (ctDNA) n resectable pancreatic ductal adenocarcinoma (PDAC)

被引：0
|
作者：
Wong, H-L. [1 ]
Bushell, K. [2 ]
Karasinska, J. [3 ]
Arthur, S. [2 ]
Pararajalingam, P. [2 ]
Morin, R. [2 ]
Schaeffer, D. F. [4 ]
Renouf, D. J. [1 ]
机构：
[1] BC Canc Agcy, Div Med Oncol, Vancouver, BC, Canada
[2] Simon Fraser Univ, Dept Mol Biol & Biochem, Vancouver, BC, Canada
[3] Pancreas Ctr BC, Vancouver, BC, Canada
[4] Vancouver Gen Hosp, Div Anat Pathol, Vancouver, BC, Canada
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
10.1093/annonc/mdw371.79
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
687P
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Clinical impact of visceral thrombosis (VT) in pancreatic ductal adenocarcinoma (PDAC).
    Hicks, Angel Mier
    Raj, Micheal
    Do, Richard Kinh Gian
    Yu, Kenneth H.
    Lowery, Maeve Aine
    Varghese, Anna M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [42] Clinical impact of KRAS mutations in metastatic pancreatic ductal adenocarcinoma (PDAC)
    Norton, Carter
    Smith, Jarrod
    Rubnitz, Zach
    Tan, Grace H.
    Nevala-Plagemann, Christopher Duane
    Soares, Heloisa P.
    Garrido-Laguna, Ignacio
    Florou, Vaia
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 619 - 619
  • [43] Overexpression of Mesothelin in Pancreatic Ductal Adenocarcinoma (PDAC)
    Le, Kai
    Wang, Jia
    Zhang, Tao
    Guo, Yifan
    Chang, Hong
    Wang, Siyuan
    Zhu, Bin
    [J]. INTERNATIONAL JOURNAL OF MEDICAL SCIENCES, 2020, 17 (04): : 422 - 427
  • [44] Pancreatic ductal adenocarcinoma (PDAC) early detection
    Hinestrosa, Juan P.
    Dhani, Harmeet
    Schroeder, Gregor
    Lewis, Jean M.
    Balcer, Heath I.
    Kurzrock, Razelle
    Keith, Dove
    Sears, Rosalie
    Billings, Paul
    [J]. CANCER RESEARCH, 2023, 83 (07)
  • [45] Therapeutic trends in pancreatic ductal adenocarcinoma (PDAC)
    Chandana, Sreenivasa
    Babiker, Hani M.
    Mahadevan, Daruka
    [J]. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2019, 28 (02) : 161 - 177
  • [46] Analysis of plasma circulating tumor DNA in borderline resectable pancreatic ductal adenocarcinoma treated with neoadjuvant modified FOLFIRINOX: Clinical relevance of DNA damage repair gene alterations.
    Lim, Dong-Hoon
    Hyung, Jaewon
    Lee, Sang Soo
    Jeong, Jae Ho
    Ryoo, Baek-Yeol
    Kim, Kyu-Pyo
    Yoo, Changhoon
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 737 - 737
  • [47] The utility of PD-L1 as a prognostic marker in pancreatic ductal adenocarcinoma (PDAC).
    Wu, Linda
    Fulop, Daniel Jeremy
    Rudshteyn, Michelle
    Shah, Nagma
    Hill-Oliva, Michael
    Sohval, Sophie
    Gandhi, Sonal
    Chowdhury, Nobel
    Debnath, Neha
    Cohen, Deirdre Jill
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 753 - 753
  • [48] Diagnostic and prognostic value of KRAS mutations in circulating pancreatic ductal adenocarcinoma tumor DNA
    Yang, Xiaowei
    Xu, Wei
    Tian, Xiuyun
    Wu, Jianhui
    Lv, Ang
    Li, Chengpeng
    Guan, Xiaoya
    Qian, Honggang
    Hao, Chunyi
    [J]. TRANSLATIONAL CANCER RESEARCH, 2018, 7 (03) : 622 - 633
  • [49] Diagnostic and Prognostic Value of Circulating KRAS Mutations in Resectable Pancreatic Ductal Adenocarcinoma
    Hipp, J.
    Hussung, S.
    Duyster, J.
    Fichtner-Feigl, S.
    Fritsch, R.
    Wittel, U. A.
    [J]. PANCREAS, 2018, 47 (10) : 1392 - 1392
  • [50] Mast cells in the tumor microenvironment are essential for the tumorigenesis of pancreatic ductal adenocarcinoma (PDAC)
    Ma, Ying
    Ji, Baoan
    Wang, Huamin
    Liu, Yan
    Deng, Defeng
    McQuade, Jennifer
    Overwijk, Willem
    Lizee, Gregory
    Abbruzzese, James
    Liu, Yong-Jun
    Hwu, Patrick
    Logsdon, Craig
    Ulrich, Stephen
    Chang, David
    [J]. CANCER RESEARCH, 2009, 69
12345